Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Feb 18;9:2208. doi: 10.1038/s41598-018-38086-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Frequency of abnormalities in ITP patients. (A) Venn diagram showing the number of patients/samples displaying increased platelet apoptosis, increased platelet desialylation and/or inhibition of proplatelet formation (PPF) in the ITP population studied (n = 20). (B) Incidence of platelet apoptosis (Apo), platelet desialylation (Desial) and inhibition of PPF (PPF) in patients according to the presence (with Abs) or absence (without Abs) of autoantibodies (Fisher’s exact test, *P < 0.05). (C) Percentage of ITP patients with detectable levels of platelet autoantibodies according to the number of defects observed (Group 0-1, patients harbouring none or only one defect, including inhibition in PPF, increased platelet desialylation or apoptosis; Group 2, patients with 2 abnormalities; Group 3, patients displaying impaired PPF, increased platelet desialylation and platelet apoptosis) (Chi-square test, ***P < 0.001).